Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with In Vitro and In Vivo Activity against Dengue and Other Flaviviruses-Reference-Cited by-同舟云学术

Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with In Vitro and In Vivo Activity against Dengue and Other Flaviviruses

Published:2021-10-18 Issue:11 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Good Steven S.¹^ORCID,Shannon Ashleigh²,Lin Kai¹,Moussa Adel¹,Julander Justin G.³^ORCID,La Colla Paolo⁴,Collu Gabriella⁴,Canard Bruno²,Sommadossi Jean-Pierre¹

Affiliation:

1. Atea Pharmaceuticals, Inc., Boston, Massachusetts, USA

2. Architecture et Fonction des Macromolécules Biologiques, Marseille, France

3. Institute for Antiviral Research, Utah State University, Logan, Utah, USA

4. Dipartimento di Scienze e Tecnologie Biomediche, Università degli Studi di Cagliari, Monserrato, Italy

Abstract

Every year, millions of people worldwide are infected with dengue virus (DENV), with a significant number developing severe life-threatening disease. There are currently no broadly indicated vaccines or therapeutics available for treatment of DENV infection.

Funder

Atea Pharmaceuticals, Inc.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00988-21

Reference32 articles.

1. Arbovirus surveillance: first dengue virus detection in local Aedes albopictus mosquitoes in Europe, Catalonia, Spain, 2015

2. The 2012 dengue outbreak in Madeira: exploring the origins

3. Dengue Antiviral Development: A Continuing Journey